BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 9463745)

  • 1. Pleural fluid pseudouridine in malignant and benign pleural effusions.
    Mak TW; Ho SS; Ho CS; Jones MG; Lai CK; Lam CW
    Ann Clin Biochem; 1998 Jan; 35 ( Pt 1)():94-8. PubMed ID: 9463745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions.
    Porcel JM; Vives M; Esquerda A; Salud A; Pérez B; Rodríguez-Panadero F
    Chest; 2004 Dec; 126(6):1757-63. PubMed ID: 15596670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The value of B7-H4 and carcinoembryonic antigen in diagnosing the benign and malignant pleural effusion].
    Wei F; Wei Y; Li LF; Li GL; Wang GJ
    Zhonghua Zhong Liu Za Zhi; 2017 Jul; 39(7):524-527. PubMed ID: 28728299
    [No Abstract]   [Full Text] [Related]  

  • 4. Assessment of a panel of tumor markers for the differential diagnosis of benign and malignant effusions by well-based reverse phase protein array.
    Braunschweig T; Chung JY; Choi CH; Cho H; Chen QR; Xie R; Perry C; Khan J; Hewitt SM
    Diagn Pathol; 2015 May; 10():53. PubMed ID: 26022333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic value of sialic acid in malignant pleural effusions.
    Imecik O; Ozer F
    Chest; 1992 Dec; 102(6):1819-22. PubMed ID: 1446495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homocysteine: new tumor marker in pleural fluid.
    Santotoribio JD; Cañavate-Solano C; Garcia-de la Torre A; Del Valle-Vazquez L; Arce-Matute F; Cuadros-Muñoz JF; Sanchez del Pino MJ; Bandez-Ruiz MJ; Piñuela-Rojas C; Perez-Ramos S
    Tumour Biol; 2015 Sep; 36(10):7941-5. PubMed ID: 25956279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of pleural fluid C-reactive protein in laboratory diagnosis of pleural effusions.
    Castaño Vidriales JL; Amores Antequera C
    Eur J Med; 1992; 1(4):201-7. PubMed ID: 1341445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Procalcitonin as a diagnostic marker in differentiating parapneumonic effusion from tuberculous pleurisy or malignant effusion.
    Lee SH; Lee EJ; Min KH; Hur GY; Lee SY; Kim JH; Shin C; Shim JJ; In KH; Kang KH; Lee SY
    Clin Biochem; 2013 Oct; 46(15):1484-8. PubMed ID: 23570862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different expression of FoxM1 in human benign and malignant pleural effusion.
    Tang Z; Li H; Zhu H; Bai C
    Med Oncol; 2015 Jan; 32(1):312. PubMed ID: 25491139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical utility of a combination of tumour markers in the diagnosis of malignant pleural effusions.
    Gaspar MJ; De Miguel J; García Díaz JD; Díez M
    Anticancer Res; 2008; 28(5B):2947-52. PubMed ID: 19031938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of cytokeratin fragments 19.1 and 19.21 (Cyfra 21-1) in the differentiation of malignant and benign pleural effusions.
    Lee YC; Knox BS; Garrett JE
    Aust N Z J Med; 1999 Dec; 29(6):765-9. PubMed ID: 10677119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic value of CA 72-4, carcinoembryonic antigen, CA 15-3, and CA 19-9 assay in pleural fluid. A study of 207 patients.
    Villena V; López-Encuentra A; Echave-Sustaeta J; Martín-Escribano P; Ortuño-de-Solo B; Estenoz-Alfaro J
    Cancer; 1996 Aug; 78(4):736-40. PubMed ID: 8756365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas.
    Sriram KB; Relan V; Clarke BE; Duhig EE; Windsor MN; Matar KS; Naidoo R; Passmore L; McCaul E; Courtney D; Yang IA; Bowman RV; Fong KM
    BMC Cancer; 2012 Sep; 12():428. PubMed ID: 23009708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limited additive value of pleural fluid carcinoembryonic antigen level in malignant pleural effusion.
    Riantawan P; Sangsayan P; Bangpattanasiri K; Rojanaraweewong P
    Respiration; 2000; 67(1):24-9. PubMed ID: 10705258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of soluble B7-H4 and carcinoembryonic antigen in distinguishing malignant from benign pleural effusion.
    Jing X; Wei F; Li J; Dai L; Wang X; Jia L; Wang H; An L; Yang Y; Zhang G; Cheng Z
    Clin Respir J; 2018 Mar; 12(3):986-990. PubMed ID: 28127951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactive oxygen species modulator 1 (Romo1) as a novel diagnostic marker for lung cancer-related malignant effusion.
    Lee SH; Park MJ; Choi SI; Lee EJ; Lee SY; In KH
    Medicine (Baltimore); 2017 Jan; 96(4):e5975. PubMed ID: 28121949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CEA and CA 549 in serum and pleural fluid of patients with pleural effusion.
    Hernández L; Espasa A; Fernández C; Candela A; Martín C; Romero S
    Lung Cancer; 2002 Apr; 36(1):83-9. PubMed ID: 11891038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic usefulness of tumour marker levels in pleural effusions of malignant and benign origin.
    Kuralay F; Tokgöz Z; Cömlekci A
    Clin Chim Acta; 2000 Oct; 300(1-2):43-55. PubMed ID: 10958862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble receptor-binding cancer antigen expressed on SiSo cells in pleural fluid: a potential diagnostic marker for malignant pleural effusion.
    Aoe K; Hiraki A; Maeda T; Murakami T; Yamazaki K; Sugi K; Takeyama H
    Chest; 2004 Oct; 126(4):1195-7. PubMed ID: 15486382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of pleural complement activation products in differentiating tuberculosis and malignant effusions.
    Porcel JM; Vives M; Gázquez I; Vicente de Vera MC; Pérez B; Rubio M
    Int J Tuberc Lung Dis; 2000 Jan; 4(1):76-82. PubMed ID: 10654648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.